RxDoctor Payments Data

Adnan Kiani, MD

Rheumatology · Cedar Rapids, IANPI 1548611841

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.8% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Amgen at 36.0% of the total. Reporting peaked in 2022 at $1,310 and has fallen 95.8% since, to $55 in 2024.

$1,757in general payments, 2019–2025

Across 100 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$633
  • Johnson & Johnson$320
  • Mallinckrodt Hospital Products Inc.$164
  • Novartis$160
  • UCB, Inc.$113
  • GSK$92
  • plus $276 from 7 others

What the payments were for

  • Food & beverage$1,68396%
  • Education$754%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,757 in reported general payments places this provider in the 85th percentile of 50 rheumatology providers in Iowa.

See all rheumatology providers in Iowa

Medicare billing

Part B allowed, 2024
$1,635,071
Medicare patients
550
Services billed
110,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab68$617,533
Enbrel SureclickEtanercept23$166,795
Humira(Cf)Adalimumab18$148,522
Orencia ClickjectAbatacept21$126,031
ForteoTeriparatide15$64,961
Hydroxychloroquine Sulfate313$12,508
MethotrexateMethotrexate Sodium386$8,951
Leflunomide108$5,742
Mycophenolate Mofetil37$5,689
Prednisone401$2,978
Sulfasalazine37$1,358
Duloxetine Hcl43$1,312
Sulfasalazine DrSulfasalazine17$1,061
Azathioprine33$933
Gabapentin67$857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$13$148,52218 claims
Lilly USA, LLCForteo$20$64,96115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 50 rheumatology providers in Iowa.

Other rheumatology in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →